The Knowledge And Mileage Podcast

GLP-1s have dominated the headlines, but the next wave of compounds is already here, and they’re changing the conversation on fat loss, performance, and longevity. In this episode, I break down the science behind four emerging therapies and why you need to know about them now. We cover how Afoglipron, the first oral non-peptide GLP-1, removes the barrier of injections while delivering results on par with semaglutide. You’ll hear why Teriparatide, originally used for osteoporosis, may reduce visceral fat and protect bone density at the same time. I also dive into Mazdutide, a dual GLP-1/glucagon agonist that suppresses appetite while boosting energy expenditure, and Tesofensine, a brain-targeting appetite suppressant with powerful effects on cravings. I share what the latest clinical data shows, the benefits and risks for both general populations and athletes, and how these compounds could fit into the bigger picture of training, nutrition, and longevity. This is a must-listen. What's Discussed: 00:05 — Why GL